Akebia Therapeutics (AKBA) has provided an update.
Akebia Therapeutics, Inc. has made a significant stride in the healthcare market with the FDA’s approval of its new drug, Vafseo® (vadadustat), aimed at treating anemia in adults with chronic kidney disease on dialysis. This milestone is likely to capture the attention of investors and market watchers due to its potential impact on the company’s growth and presence in the pharmaceutical sector.
Find detailed analytics on AKBA stock on TipRanks’ Stock Analysis page.
